

Nexus Alliance Biopharmaceuticals (NAB).

SCP- Oncology.

Overall

- ✓ **Regulatory:** ANDA, 505 (b)2 process; Right to Try, and additional designations, with multiple IP expansions.
- ✓ **CMC:** Easy to skill- up as opposed to any reformulation and reengineering compounding (eg. Liposomes and NAB).
- ✓ **ROI:** The quickest cash positive revenue in the early R&D space. No acquisition of new assets is required. A rich joint space, combination therapy, asset sales, are few potential selected strategies.
- ✓ Expedited approval targeted indications, including solid tumors with minimal IO success.
- ✓ **Product Diversification:** More than 114 products available with a similar platform and variations of the IP.
- ✓ **HEOR:** Perfect landscape to save on drug cost, while reducing the cost of managing the known adverse events, while improve the efficacy of the predicated competition.
- ✓ **Clinical Feasibility:** The products, the mechanism of actions, their reengineering phenomenon are well appreciated and understood by the conventional practitioners. Combination therapy and co- branding to maximize value- based program expansions. [Published SCP's positive RWE data in the most aggressive solid tumors .](#)



Executive Summary

1. Global Allied Pharmaceuticals (GAP) was founded in 2002 by biopharma professionals as a CRO.
2. NAB: A focused company in oncology research/ R&D was developed in 2004 by the same founders.
3. GAP- NAB: A niched clinical research and discovery team with an IP protected platform known as Smart Conjugate Particle (SCP) technology.

SCP: ABCD- Perfect

- A. SCP is practical to develop, approve, commercialize.
- B. Turning hydrophobes into targeted water soluble and stable 100th 1000th of micro- structure.
- C. SCP- Oncology: Proven Clinical Track Record via [Published Clinical Data](#).
- D. SCP: Easy to scale up in production stable to deliver to patients.

SWOT Analysis

Strength

- Cost competitiveness
- Acquisition of Arvind Remedies, INDIA
- Unique Product launch(SCP&ADC)
- Robust R&D

Weakness

- Initial investment costs
- Strict Govt. regulations and policies affects operational efficiency
- Low R&D investment compared to global standards

Opportunities

- Pioneers in producing SCP & other unique Products
- Indication expansion (Oncology, Immune Oncology etc..)
- Overseas expansion
- Leverage biologics & cytotoxic infrastructure to deal with the need of oncology market

Threats

- Increasingly stringent regulations for new drug development
- Economic crisis
- Ethical pressure
- Prices of raw materials fluctuate highly
- Highly regulated Industry



Industry Background

An Example (1/114)



SCP: SCP Tech.

Docetaxel-X

Next Generation Drug
Delivery

Systems SCP- Engineering.

We are targeting the top most popular backbone
mono and combination therapies in SCP™.



A winning leadership

✓ ***Timothy Allen, MD, PhD:***

More than 14 years of in R&D of biopharma, training in internal medicine and Hem. Oncology with fellowship at FDA and CIOMS. Member of ODAC- FDA advisory support group and EMA- Oncology forum. Co- founder of GAP and

✓ ***Ariel (Nepton) Sheikh- Khoni, MD:***

More than 12 years in R&D of biopharma, training in internal medicine and research fellowship in Oncology. President of Nexus Alliance Biopharma.

✓ ***Ghazaleh Shoja, MD:***

More than 20 years in R&D and practice in Hem. Oncology. Trained in Hem. Oncology and fellowship in transplantation. Trained in Italy, the US and Canada. A current attending physician in Canada.



Questions

Please contact:

Timothy Allen, MD, PhD.

VP of Medical/Clinical Operations.

Board Member.

Global Lead Clinician, Clinical Development and Medical Affairs

Timothy.Allen@takechargemedical.com

Tele#: 321-945-4283

www.takechargemedical.com

www.nexusalliancebiopharma.com

